Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 20,246 shares, a decrease of 87.2% from the June 30th total of 158,023 shares. Based on an average daily volume of 9,139 shares, the short-interest ratio is currently 2.2 days. Approximately 0.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.43.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Finally, UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period.

Ascentage Pharma Group International Trading Up 2.3%

Shares of NASDAQ AAPG traded up $0.42 during midday trading on Monday, hitting $18.71. The company’s stock had a trading volume of 1,368 shares, compared to its average volume of 6,928. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a 1-year low of $16.36 and a 1-year high of $48.45. The firm’s fifty day moving average price is $18.56 and its 200-day moving average price is $22.38.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.